Եվրոպական Միություն - իսպաներեն - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - inmunosupresores - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Եվրոպական Միություն - իսպաներեն - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - los sueros inmunes e inmunoglobulinas, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. ver secciones 4. 4 y 5.

Եվրոպական Միություն - իսպաներեն - EMA (European Medicines Agency)

chemical works of gedeon richter plc. (gedeon richter plc.) - ganirelix acetate - reproductive techniques, assisted; ovulation induction; infertility, female - hormonas hipofisarias e hipotalámicas y análogos - prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).

Եվրոպական Միություն - իսպաներեն - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - linfoma, folicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Եվրոպական Միություն - իսպաներեն - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmológicos - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Էկվադոր - իսպաներեն - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

quimica ariston ecuador cia. ltda [ec] ecuador - aciclovir (cas nÚmero registrado: 59277-89-3) 200 mg - suspensiÓn oral - cada 5.0 ml. de suspensiÓn oral contiene: aciclovir (cas nÚmero registrado: 59277-89-3) 200 mg

Էկվադոր - իսպաներեն - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

quimica ariston ecuador cia. ltda. [ec] ecuador - meloxicam 7,50 mg (cas nÚmero registrado: 71125-38-7) - suspensiÓn oral - cada 5,0 ml de suspensión oral contiene: meloxicam 7,50 mg (cas nÚmero registrado: 71125-38-7)

Էկվադոր - իսպաներեն - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

laboratorios siegfried s.a. [ec] ecuador - meloxicam 15.00 mg (cas nÚmero registro: 71125-38-7) - comprimidos  - cada comprimido contiene: meloxicam 15.00 mg (cas nÚmero registro: 71125-38-7)

Էկվադոր - իսպաներեն - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

gedeon richter plc., hungria - folitropina alfa (rhfsh) 450ui (33ug)/0,75 ml - soluciÓn inyectable - cada 0,75 ml de solución inyectable contiene: folitropina alfa (rhfsh) 450ui (33ug)

Էկվադոր - իսպաներեն - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

gedeon richter plc., hungria - folitropina alfa (rhfsh) 300ui (22ug) - soluciÓn inyectable - cada 0,5 ml de solución inyectable contiene: folitropina alfa (rhfsh) 300ui (22ug)